Download a copy of our poster titled, 'A Phase I, open-label, 2-Part study to establish absolute bioavailability'. A Phase I, open-label, 2-Part study to establish absolute bioavailability and the ADME of evogliptin in healthy male subjects by light-label approach.
Have a question about your next human ADME program or other clinical pharmacology programs that we offer? Ask a member of our team about our capabilities.
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About AndrewSenior Director, 14C Enabled Drug Development
Iain Shaw has over 30 years of experience in the pharmaceutical industry, including over 15 years focused on 14C-enabled drug deve...
About IainSenior Manager, 14C Enabled Drug Development
Dr. Adam Robinson-Miller has more than a decade of experience in the pharmaceutical and OTC environments, with particular focus on...
About Adam